Siepen, F. a. d., Meissner, C., Hofmann, E. C. M., Hein, S., Nagel, C., Hegenbart, U., . . . Kristen, A. (2024). Response to therapy with tafamidis 61 mg in patients with cardiac transthyretin amyloidosis: Real-world experience since approval. Amyloid, 31(3), . https://doi.org/10.1080/13506129.2024.2376202
Chicago-Zitierstil (17. Ausg.)Siepen, Fabian aus dem, et al. "Response to Therapy with Tafamidis 61 Mg in Patients with Cardiac Transthyretin Amyloidosis: Real-world Experience Since Approval." Amyloid 31, no. 3 (2024). https://doi.org/10.1080/13506129.2024.2376202.
MLA-Zitierstil (9. Ausg.)Siepen, Fabian aus dem, et al. "Response to Therapy with Tafamidis 61 Mg in Patients with Cardiac Transthyretin Amyloidosis: Real-world Experience Since Approval." Amyloid, vol. 31, no. 3, 2024, https://doi.org/10.1080/13506129.2024.2376202.